- Home
- NRIM vs VERV Comparison
NRIM vs VERV Comparison
Compare NRIM & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIM
- VERV
- Stock Information
- Founded
- NRIM 1990
- VERV 2018
- Country
- NRIM United States
- VERV United States
- Employees
- NRIM N/A
- VERV N/A
- Industry
- NRIM Savings Institutions
- VERV Medicinal Chemicals and Botanical Products
- Sector
- NRIM Finance
- VERV Health Care
- Exchange
- NRIM Nasdaq
- VERV Nasdaq
- Market Cap
- NRIM 474.2M
- VERV 475.0M
- IPO Year
- NRIM N/A
- VERV 2021
- Fundamental
- Price
- NRIM $84.00
- VERV $5.38
- Analyst Decision
- NRIM
- VERV Strong Buy
- Analyst Count
- NRIM 0
- VERV 4
- Target Price
- NRIM N/A
- VERV $25.75
- AVG Volume (30 Days)
- NRIM 24.3K
- VERV 1.6M
- Earning Date
- NRIM 01-23-2025
- VERV 11-05-2024
- Dividend Yield
- NRIM 2.88%
- VERV N/A
- EPS Growth
- NRIM 22.45
- VERV N/A
- EPS
- NRIM 5.86
- VERV N/A
- Revenue
- NRIM $141,590,000.00
- VERV $24,396,000.00
- Revenue This Year
- NRIM N/A
- VERV $97.47
- Revenue Next Year
- NRIM $3.03
- VERV N/A
- P/E Ratio
- NRIM $14.67
- VERV N/A
- Revenue Growth
- NRIM 12.70
- VERV 219.91
- 52 Week Low
- NRIM $43.92
- VERV $4.31
- 52 Week High
- NRIM $91.72
- VERV $19.34
- Technical
- Relative Strength Index (RSI)
- NRIM 51.76
- VERV 44.33
- Support Level
- NRIM $83.29
- VERV $5.19
- Resistance Level
- NRIM $89.11
- VERV $7.40
- Average True Range (ATR)
- NRIM 2.54
- VERV 0.65
- MACD
- NRIM -0.89
- VERV -0.12
- Stochastic Oscillator
- NRIM 5.84
- VERV 7.88
About NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The company operates in two segments: Community Banking and Home Mortgage Lending. It generates maximum revenue from the Community Banking segment. It offers to spend and save products such as checking, savings, money market accounts, debit cards, cashback rewards, and credit cards. It also includes loans and credit lines, mortgage loans, investment, and plan products.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.